



The novel platform will enable regulators and industry to identify, quantify and prevent cardiotoxic co-exposures to industrial chemicals and pharmaceuticals in a cost-effective way.

A European Green Deal
Striving to be the first climate-neutral continent

ALTERNATIVE has received funding from the European Commission under the European Union's Horizon 2020 programme. The European Union has no responsibility for the content of this publication.





BUILDING THE INNOVATIVE PLATFORM FOR DETECTING THE CARDIOTOXICITY OF CHEMICALS

https://alternative-project.eu/

CONTACT DETAILS







@EU_ALTERNATIVE







Environmental toxicity chemical mixtures through an innovative platform based on aged cardiac tissue model






CONSORTIUM PARTNERS







ALTERNATIVE

Building the Innovative Platform to Assess the Cardiotoxicity of Chemicals and their bio-transformation products



0

ALTERNATIVE novel platform will enable regulators and industry to identify, quantify and prevent cardiotoxic co-exposures to industrial chemicals and pharmaceuticals in a cost-effective way.



MACHINE LEARNING

The platform will be coupled with a reliable, high-throughput monitoring system based on multi-omics analyses, and integrated into a Machine Learning (ML) risk assessment tool.

The platform will consist of a three-dimensional tissue engineering invitro model mimicking the human cardiac tissue.





In addition, ALTERNATIVE will modify the tissue model to reproduce the aged myocardial tissue and elucidate the adverse effects of chemicals on older people.

DECISION-HELPER

ALTERNATIVE will also provide systematic reviews of high-quality epidemiological studies to support integrated in-vitro and insilico data, giving a more robust basis for regulatory decisions.

ALTERNATIVE's proof-ofconcept validation will be performed on well-known mixtures of pollutants, affecting different environmental compartments, and selected via epidemiological, toxicological and modelling expertise.



ALTERNATIVE platform will be an

Innovative tool

for complying with the current regulation associated with the assessment of chemical compounds. It will be a new instrument to evaluate unpredictable toxicity due to synergistic effects of different chemicals, additionally worsened by the human ageing process.

Developement of human-relevant non-animal based methods

Needs

Cost-effective

histopathology, cardiac Knowledge gaps

In vivo testing

Current regulator

- MoA identification difficult

